Achillion Pharmaceuticals (ACHN) Lowered to “Strong Sell” at BidaskClub

Share on StockTwits

BidaskClub cut shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a strong sell rating in a report published on Friday.

Separately, Zacks Investment Research upgraded Achillion Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, June 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. Achillion Pharmaceuticals has an average rating of Hold and a consensus target price of $4.38.

ACHN stock traded up $0.05 during trading on Friday, hitting $3.13. 952,353 shares of the company traded hands, compared to its average volume of 1,459,196. The stock has a market cap of $510.00 million, a P/E ratio of -5.05 and a beta of 1.27. Achillion Pharmaceuticals has a 1 year low of $2.33 and a 1 year high of $4.63.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. Research analysts anticipate that Achillion Pharmaceuticals will post -0.52 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. Northern Trust Corp increased its position in shares of Achillion Pharmaceuticals by 1.9% in the second quarter. Northern Trust Corp now owns 1,604,822 shares of the biopharmaceutical company’s stock valued at $4,541,000 after buying an additional 30,669 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Achillion Pharmaceuticals in the second quarter valued at approximately $147,000. Bank of America Corp DE increased its position in shares of Achillion Pharmaceuticals by 14.5% in the second quarter. Bank of America Corp DE now owns 416,817 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 52,634 shares in the last quarter. RTW Investments LP increased its position in shares of Achillion Pharmaceuticals by 0.3% during the second quarter. RTW Investments LP now owns 13,541,997 shares of the biopharmaceutical company’s stock worth $38,324,000 after purchasing an additional 45,095 shares in the last quarter. Finally, BlueMountain Capital Management LLC purchased a new stake in shares of Achillion Pharmaceuticals during the second quarter worth approximately $159,000. Institutional investors and hedge funds own 78.36% of the company’s stock.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Featured Article: Price to Earnings Ratio (PE) Basics

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Biogen  Upgraded to Buy by BidaskClub
Biogen Upgraded to Buy by BidaskClub
Achillion Pharmaceuticals  Lowered to “Strong Sell” at BidaskClub
Achillion Pharmaceuticals Lowered to “Strong Sell” at BidaskClub
Fidelity National Financial  Trading Down 7.8%
Fidelity National Financial Trading Down 7.8%
Diebold Nixdorf  Stock Price Down 9.6%
Diebold Nixdorf Stock Price Down 9.6%
Omicron Hits One Day Trading Volume of $1.00
Omicron Hits One Day Trading Volume of $1.00
The ChampCoin  Price Tops $0.0037 on Exchanges
The ChampCoin Price Tops $0.0037 on Exchanges


Leave a Reply

© 2006-2018 Ticker Report. Google+.